Santyl Generic Name: collagenase Brand Name: Santyl Drug Class: side effects drug center santyl (collagenase) drug Related Drugs Avagard Foam Avagard Lotion Health Resources Burns (First Aid) Peptic Ulcer (Stomach Ulcer) Related Supplements Honey Zinc Santyl User Reviews PROFESSIONAL CONSUMER SIDE EFFECTS Contents Drug Description Indications & Dosage Side Effects & Drug Interactions Warnings & Precautions Overdosage & Contraindications Clinical Pharmacology Medication Guide Drug Description What is Santyl and how is it used?Santyl is a prescription medicine used to treat the symptoms of Dermal Ulcers. Santyl may be used alone or with other medications.Santyl belongs to a class of drugs called Wound Care.It is not known if Santyl is safe and effective in children.What are the possible side effects of Santyl?Santyl may cause serious side effects including:hives,difficulty breathing,swelling of your face, lips, tongue or throat,worsening skin conditions, andsigns of infection (fever, redness, swelling)Get medical help right away, if you have any of the symptoms listed above.The most common side effects of Santyl include:redness of the skin around the treated areaTell the doctor if you have any side effect that bothers you or that does not go away.These are not all the possible side effects of Santyl. For more information, ask your doctor or pharmacist.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. DESCRIPTIONCollagenase Santyl® Ointment is a sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme collagenase is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. Indications & Dosage INDICATIONS Collagenase Santyl® Ointment is indicated for debriding chronic dermal ulcers2,3,4,5,6,8,9,10,11,12,13,14,15,16,17,18 and severely burned areas.3,4,5,7,16,19,20,21 DOSAGE AND ADMINISTRATION Collagenase Santyl® Ointment should be applied once daily (or more frequently if the dressing becomes soiled, as from incontinence). When clinically indicated, crosshatching thick eschar with a #10 blade allows Collagenase Santyl® Ointment more surface contact with necrotic debris. It is also desirable to remove, with forceps and scissors, as much loosened detritus as can be done readily. Use Collagenase Santyl® Ointment in the following manner: Prior to application the wound should be cleansed of debris and digested material by gently rubbing with a gauze pad saturated with normal saline solution, or with the desired cleansing agent compatible with Collagenase Santyl® Ointment (See PRECAUTIONS), followed by a normal saline solution rinse. Whenever infection is present, it is desirable to use an appropriate topical antibiotic powder. The antibiotic should be applied to the wound prior to the application of Collagenase Santyl® Ointment. Should the infection not respond, therapy with Collagenase Santyl® Ointment should be discontinued until remission of the infection. Collagenase Santyl® Ointment may be applied directly to the wound or to a sterile gauze pad which is then applied to the wound and properly secured. Use of Collagenase Santyl® Ointment should be terminated when debridement of necrotic tissue is complete and granulation tissue is well established. HOW SUPPLIED Collagenase Santyl® Ointment contains 250 units of collagenase enzyme per gram of white petrolatum USP. Do not store above 25°C (77°F). Sterility guaranteed until tube is opened. Collagenase Santyl® Ointment is available in the following sizes: 30 g tube NDC 50484-010-30 90 g tube NDC 50484-010-90 REFERENCES 2 - Boxer, A.M., Gottesman, N., Bernstein, H., & Mandl, I., Geriatrics. 24:75, 1969. 3 - Mazurek, I., Med. Welt. 22:150, 1971. 4 - Zimmermann, WE., in “Collagenase,” Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 131, p. 185. 5 - Vetra, H., & Whittaker, D., Geriatrics. 30:53, 1975. 6 - Rao, D.B., Sane, P.G., & Georgiev, E.L., J. Am. Geriatrics Soc. 23:22, 1975. 7 - Vrabec, R., Moserova, J., Konickova, Z., Behounkova, E., & Blaha, J., J. Hyg. Epidemiol. Microbiol. Immunol. 18:496, 1974. 8 - Lippmann, H.I., Arch. Phys. Med. Rehabil. 54:588, 1973. 9 - German, F. M., in “Collagenase,” Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 165. 10 - Haimovici, H. & Strauch, B., in “Collagenase,” Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 177. 11 - Lee, L.K., & Ambrus, J.L., Geriatrics. 30:91, 1975. 12 - Locke, R.K., & Heifitz, N.M., J. Am. Pod. Assoc. 65:242, 1975. 13 - Varma, A.O., Bugatch, E., & German, F.M., Surg. Gynecol. Obstet. 136:281, 1973. 14 - Barrett, D., Jr., & Klibanski, A., Am. J. Nurs. 73:849, 1973. 15 - Bardfeld, L.A., J. Pod. Ed. 1:41, 1970. 16 - Blum, G., Schweiz, Rundschau Med Praxis. 62:820, 1973. Abstr. in Dermatology Digest, Feb. 1974, p. 36. 17 - Zaruba, F., Lettl, A., Brozkova, L., Skrdlantova, H., & Krs, V., J. Hyg. Epidemiol. Microbiol. Immunol. 18:499, 1974. 18 - Altman, M.I., Goldstein, L., & Horwitz, S., J. Am. Pod. Assoc. 68:11, 1978. 19 - Rehn, V.J., Med. Klin. 58:799, 1963. 20 - Krauss, H., Koslowski, L., & Zimmermann, W. E., Langenbecks Arch. Klin. Chir. 303:23, 1963. 21 - Gruenagel, H.H., Med. Klin. 58:442, 1963. Manufactured by: SMITH & NEPHEW, INC, Fort Worth, Texas 76109. Marketed by: Smith & Nephew, Inc., Fort Worth, Texas 76109. Revised: Mar 2017 Side Effects & Drug Interactions SIDE EFFECTS No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. However, one case of systemic manifestations of hypersensitivity to collagenase in a patient treated for more than one year with a combination of collagenase and cortisone has been reported. DRUG INTERACTIONS No information provided. Warnings & Precautions WARNINGS No information provided. PRECAUTIONS The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. When it is suspected such materials have been used, the site should be carefully cleansed by repeated washings with normal saline before Collagenase Santyl® Ointment is applied. Soaks containing metal ions or acidic solutions should be avoided because of the metal ion and low pH. Cleansing materials such as Dakin's solution and normal saline are compatible with Collagenase Santyl® Ointment. Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia. A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when Collagenase Santyl Ointment was not confined to the wound. Therefore, the ointment should be applied carefully within the area of the wound. Safety and effectiveness in pediatric patients have not been established. Overdosage & Contraindications OVERDOSE No systemic or local reaction attributed to overdose has been observed in clinical investigations and clinical use. If deemed necessary the enzyme may be inactivated by washing the area with povidone iodine. CONTRAINDICATIONS Collagenase Santyl® Ointment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase. Clinical Pharmacology CLINICAL PHARMACOLOGY Since collagen accounts for 75% of the dry weight of skin tissue, the ability of collagenase to digest collagen in the physiological pH and temperature range makes it particularly effective in the removal of detritus.1 Collagenase thus contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas.2,3,4,5,6 Collagen in healthy tissue or in newly formed granulation tissue is not attacked.2,3,4,5,6,7,8 There is no information available on collagenase absorption through skin or its concentration in body fluids associated with therapeutic and/or toxic effects, degree of binding to plasma proteins, degree of uptake by a particular organ or in the fetus, and passage across the blood brain barrier. REFERENCES 1 - Mandl, I., Adv Enzymol. 23:163, 1961. 2 - Boxer, A.M., Gottesman, N., Bernstein, H., & Mandl, I., Geriatrics. 24:75, 1969. 3 - Mazurek, I., Med. Welt. 22:150, 1971. 4 - Zimmermann, WE., in “Collagenase,” Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 131, p. 185. 5 - Vetra, H., & Whittaker, D., Geriatrics. 30:53, 1975. 6 - Rao, D.B., Sane, P.G., & Georgiev, E.L., J. Am. Geriatrics Soc. 23:22, 1975. 7 - Vrabec, R., Moserova, J., Konickova, Z., Behounkova, E., & Blaha, J., J. Hyg. Epidemiol. Microbiol. Immunol. 18:496, 1974. 8 - Lippmann, H.I., Arch. Phys. Med. Rehabil. 54:588, 1973. 9 - German, F. M., in “Collagenase,” Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 165. Medication Guide PATIENT INFORMATION No information provided. Please refer to the PRECAUTIONS section.
